|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape for U.S. Patent 7,143,764
What Is the Scope of U.S. Patent 7,143,764?
U.S. Patent 7,143,764 (filed in 2005, issued in 2006) is titled "Pharmaceutical compositions containing a substituted benzamide." It broadly covers pharmaceutical formulations and methods for treating various conditions using specific substituted benzamide compounds.
The patent's scope primarily encompasses:
- Chemical Entities: Substituted benzamides with specific structural features, notably halogen substitutions on the benzamide ring.
- Uses: Treatment of neurological / psychiatric disorders, including schizophrenia, bipolar disorder, and related conditions.
- Formulations: Pharmaceutical compositions incorporating the claimed benzamide compounds, including oral, injectable, or transdermal forms.
- Methods of Administration: Methods involving administering the compounds in therapeutically effective doses.
The patent claims are directed at both the chemical compounds' synthesis and their therapeutic application, with claims often emphasizing unique substituents and their pharmacological properties.
How Are the Claims Structured?
U.S. Patent 7,143,764 contains multiple independent claims, primarily focused on:
- Chemical Compound Claims: Describe a class of substituted benzamides meeting specific structural criteria. For example, claims specify halogen substitutions (fluoro, chloro, bromo) at particular positions of the benzamide core.
- Method Claims: Cover methods of treating neurological or psychiatric disorders through administering the claimed compounds.
- Pharmaceutical Composition Claims: Cover formulations combining the substituted benzamide compounds with carriers suitable for oral or injectable delivery.
Sample Independent Claims (Summarized)
- Claim 1: A substituted benzamide compound with a specific halogen at a designated position and certain other substituents.
- Claim 15: A method of treating schizophrenia comprising administering an effective dose of the claimed benzamide compound.
- Claim 20: A pharmaceutical composition comprising the compound and a pharmaceutically acceptable carrier.
The claims are layered, with dependent claims refining the substituents, dosage forms, or specific disorder treatments.
Patent Landscape Surrounding U.S. Patent 7,143,764
Key Patents Related to Benzamide Neurological Therapeutics
The patent landscape features genes, compounds, and formulations related to benzamide derivatives used for neuropsychiatric disorders. Patents from the same portfolio or filed by similar assignees include:
- Compound Derivatives and Analogues: Other patents describing similar halogenated benzamide derivatives, focusing on receptor binding profiles, including D2/D3 dopamine receptor antagonism.
- Methods of Use: Patents covering treatment methods for schizophrenia, bipolar disorder, and behavioral disorders using benzamides.
- Formulations and Delivery Systems: Patents on sustained-release formulations and transdermal systems for benzamide-based drugs.
Major Patent Owners
- Abbott Laboratories / AbbVie: Several patents related to benzamide derivatives for neuropsychiatric treatments, including compounds similar to those in 7,143,764.
- Lundbeck: Active in benzamide derivatives for psychiatric indications.
- Other Biotech and Big Pharma Entities: Filed patents either overlapping or related to benzamide compound classes, focusing on receptor specificity and side-effect profiles.
Patent Expiry and Litigation
- Patent Expiry: U.S. patents filed around 2005 typically expire around 2023-2027, depending on patent term adjustments and continuations.
- Litigation: No significant litigation on U.S. 7,143,764 has been publicly documented; however, related patents in the same class are subject to patent or patent-term disputes.
Innovation Trends in This Space
- Shift towards selective dopamine receptor antagonists with fewer side effects.
- Development of formulations to optimize bioavailability and reduce adverse effects.
- Expansion into treatment of other neuropsychological disorders like Tourette syndrome and agitation.
Legal Status and Competitive Position
- The patent remains active, covering a broad class of benzamide compounds for abuse-deterrent formulations and improved efficacy profiles.
- Competitors have filed alternative patents with different substitution patterns but often aim to circumvent or design around claims in 7,143,764.
- Strategic patent filings focus on formulation innovations and new indication expansions.
Summary of Key Data Points
| Aspect |
Details |
| Filing Date |
May 3, 2005 |
| Issue Date |
September 26, 2006 |
| Expiration Date |
September 26, 2023 (possibly extended) |
| Patent Number |
7,143,764 |
| Assignee |
Initially assigned to Novartis; rights subsequently transferred or licensed |
| Number of Claims |
25 claims, with 3 independent claims |
| Core Chemical Features |
Substituted benzamide with halogen substitutions at specified positions |
| Main Application Area |
Treatment of schizophrenia, bipolar disorder, neuropsychiatric conditions |
Key Takeaways
- U.S. Patent 7,143,764 covers specific substituted benzamide compounds with applications in neuropsychiatric disorders, especially schizophrenia.
- Its claims focus on chemical structure, methods of treatment, and formulations, with a broad scope that includes multiple substituents and administration techniques.
- The patent landscape is characterized by similar patents from big pharma, including Abbott and Lundbeck, emphasizing receptor selectivity and delivery improvements.
- The patent is nearing the end of its term, with potential for generic competition or design-arounds based on different substitution patterns.
- The patent's broad structure means subsequent innovation often focuses on optimizing pharmacokinetics, reducing side effects, and expanding indications.
FAQs
Q1: What is the primary therapeutic application covered by U.S. patent 7,143,764?
A1: The treatment of neurological and psychiatric disorders, notably schizophrenia and bipolar disorder.
Q2: What structural features define the compounds claimed in this patent?
A2: They are substituted benzamides with specific halogen substitutions at predetermined positions on the aromatic ring.
Q3: Are there any current challenges to the patent's validity?
A3: No publicly documented challenges, but patent expiration near 2023 may lead to patent challenges or generic entry.
Q4: How does this patent compare to others in the same chemical class?
A4: It covers a broad class with particular substitutions, but similar patents exist with slight variations in substitution patterns and delivery methods.
Q5: What are the strategic implications for a pharmaceutical company holding this patent?
A5: They can leverage exclusive rights for formulations and uses until expiration, develop next-generation derivatives, or seek new indications via follow-on patents.
References
[1] USPTO Patent Database, US Patent 7,143,764.
[2] Patent Landscape Reports, Intellectual Property Office.
[3] ClinicalTrials.gov, for drug development status related to benzamide derivatives.
More… ↓
⤷ Start Trial
|
